Cargando…
ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3 ‐ITD
Bromodomain‐containing protein 4 (BRD4) inhibitors have been clinically developed to treat acute myeloid leukemia (AML), but their application is limited by the possibility of drug resistance, which is reportedly associated with the activation of the WNT/β‐catenin pathway. Meanwhile, homoharringtoni...
Autores principales: | Qian, Yu, Zhang, Xiang, Mao, Shihui, Wei, Wenwen, Lin, Xiangjie, Ling, Qing, Ye, Wenle, Li, Fenglin, Pan, Jiajia, Zhou, Yutong, Zhao, Yanchun, Huang, Xin, Huang, Jiansong, Tong, Hongyan, Sun, Jie, Jin, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323884/ https://www.ncbi.nlm.nih.gov/pubmed/36567628 http://dx.doi.org/10.1002/1878-0261.13368 |
Ejemplares similares
-
Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
por: Wei, Wenwen, et al.
Publicado: (2022) -
The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017) -
Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2019) -
Characterization of the Newly Established Homoharringtonine- (HHT-) Resistant Cell Lines and Mechanisms of Resistance
por: Li, Fenglin, et al.
Publicado: (2022) -
Homoharringtonine Synergized with Gilteritinib Results in the Downregulation of Myeloid Cell Leukemia-1 by Upregulating UBE2L6 in FLT3-ITD-Mutant Acute Myeloid (Leukemia) Cell Lines
por: Cai, Jiayi, et al.
Publicado: (2021)